Abstract
A 69-yr-old man with bilateral and metastatic renal cell carcinoma developed progressive disease after interleukin-2 and interferon therapy. He was submitted to radical left nephrectomy, right nephron-sparing surgery, and bone metastasis removal, followed by therapy with sorafenib. At 12-mo follow-up there was a significant improvement in patient performance status and no evidence of clinical progression.
MeSH terms
-
Aged
-
Antineoplastic Agents / therapeutic use*
-
Benzenesulfonates / therapeutic use*
-
Bone Neoplasms / drug therapy*
-
Bone Neoplasms / secondary*
-
Bone Neoplasms / surgery
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / secondary*
-
Carcinoma, Renal Cell / surgery
-
Combined Modality Therapy
-
Humans
-
Kidney Neoplasms / pathology*
-
Kidney Neoplasms / surgery
-
Male
-
Niacinamide / analogs & derivatives
-
Phenylurea Compounds
-
Pyridines / therapeutic use*
-
Sorafenib
Substances
-
Antineoplastic Agents
-
Benzenesulfonates
-
Phenylurea Compounds
-
Pyridines
-
Niacinamide
-
Sorafenib